KIT and small cell lung carcinoma: 38% to 78% of SCLC specimens and 42% to 52% of SCLC cell lines have high expression of c-kit [30], [34]; therefore, more than approximately 40% of SCLC patients could potentially benefit from c-kit targeted radioimmunotherapy.